Radioimmunodetection with Monoclonal Antibodies Against Prostatic Acid Phosphatase
Carcinoma of the prostate is one of the most common tumors. In the USA, it accounts for approx. 18% of all cancers of males and 24,000 deaths annually. The initial treatment a patient receives is highly dependent on the stage of the tumor at the time of its initial recognition. Therapy chosen in view of known distant metastases is also dictated to some extent by their distribution. It would be valuable, therefore, to have a diagnostic agent that could specifically indicate the presence and extent of metastases at both the early and late stages of prostate carcinoma. Currently, we are limited to the measurement of serum acid phosphatase levels, which, while useful when elevated, are not highly sensitive; computerized tomography (CT) which cannot specifically indicate metastases or radionuclide bone scanning, while useful, is also nonspecific. The invention of monoclonal antibodies (MoAb)  provides the potential for both specificity and sensitivity in diagnostic testing. This report describes our effort to develop a radiolabeled MoAb against prostatic acid phosphatase (PAP) and use it for the radioimmunodetection (RAID) of prostatic cancer.
KeywordsImmune Complex High Pressure Liquid Chromatography Prostate Carcinoma Liver Uptake Prostatic Acid Phosphatase
Unable to display preview. Download preview PDF.
- 4.Hagan PO, Halpern SE, Chen A, Krishnan L, Frincke J, Bartholomew RM, David GS, Carlo D (in press) In vivo kinetics of radiolabeled monoclonal anti-CEA antibodies in animal models. J Nucl MedGoogle Scholar